系统性失活TREX1诱导瘤微环境的选择性炎症和激活的T细胞介导的瘤控制
Emilija Marinkovic1, Minyi Chen2, Nadja Schubert3
1University Hospital Heidelberg, Germany.
Cancer research
|May 12, 2025
概括
抑制宿主细胞中的DNase 3'-修复外核酶1 (TREX1) 增强了抗瘤T细胞免疫力. 这种方法增强了瘤的控制,克服了癌症的免疫逃避,提供了一个有前途的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 在瘤微环境内对先天免疫系统的治疗性刺激可以增强内源性抗瘤T细胞反应.
- 激活循环GMP-AMP合成酶 (cGAS) /刺激干扰素基因 (STING) 信号传递是癌症免疫疗法的关键策略.
- DNase 3'-修复外核酶1 (TREX1) 降解DNA,防止内源DNA对cGAS/STING进行自身免疫激活.
研究的目的:
- 研究TREX1无活化在宿主细胞中的治疗潜力,以控制已建立的瘤.
- 评估宿主TREX1缺乏对抗瘤T细胞免疫力和瘤微环境的影响.
主要方法:
- 诱导Trex1基因在携带瘤的小鼠宿主 (非癌症) 细胞中的失活.
- 评估I型干扰素 (IFN) 和T细胞依赖的抗瘤反应.
- 分析瘤微环境中的免疫细胞透,增殖和耗尽.
主要成果:
- 诱导宿主TREX1缺陷导致了对已建立的TREX1-竞争性瘤的改善控制.
- 主体TREX1缺陷可以选择性地增加免疫细胞透到瘤中,而不会影响其他组织.
- 系统性TREX1抑制增强了内T细胞增殖和效应细胞数量,导致瘤通过检查点抑制被排斥.
结论:
- 系统性TREX1抑制是一种可行的策略,可以加强抗瘤免疫力.
- 向TREX1可以克服癌症中的免疫逃避机制,特别是那些涉及cGAS/STING失活的免疫逃避机制.
- 这种方法有望提高癌症免疫疗法的疗效.
相关概念视频
Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
Cytotoxic T Cells-mediated Immune Response
737
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
737
Cell-mediated Immune Responses
66.1K
Overview
66.1K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
T Cell Types and Functions
638
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
638
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K


